Last reviewed · How we verify

NCT06645301

BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies

Not yet recruiting EARLY_PHASE1 Last updated 16 October 2024
What this trial tests

EARLY_PHASE1 trial testing Group A in Colorectal Cancer in 15 participants. Not yet recruiting.

Timeline
30 November 2024
Primary endpoint
31 August 2026
31 August 2027

Quick facts

Lead sponsorBioSyngen Pte Ltd
PhaseEARLY_PHASE1
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date30 November 2024
Primary completion31 August 2026
Estimated completion31 August 2027

Drugs / interventions tested

Conditions studied

Sponsor

BioSyngen Pte Ltd — full company profile →

Who can join

Adults 17 to 75, any sex, with Colorectal Cancer or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an exploratory research on single arm, open, and improved "3+3" dose escalation. BGT007 will explore two dose groups, namely (Group A: 3.0X10 \^ 8 3 cases, Group B: 6.0X10 \^ 8 3 cases), and receive the same dose infusion after observing lower adverse reactions and initial benefits (SD or PR), with an interval of one month. Each subject can receive a maximum of 3 infusions in total.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Group A

Trials testing the same drug.

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

Other BioSyngen Pte Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06645301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing